NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
12.91
-0.13 (-1.00%)
At close: Mar 9, 2026, 4:00 PM EDT
12.91
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:02 PM EDT

Company Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.

Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

NovoCure Limited
NovoCure logo
Country Switzerland
Founded 2000
IPO Date Oct 2, 2015
Industry Medical Devices
Sector Healthcare
Employees 1,605
CEO Frank Leonard

Contact Details

Address:
Neuhofstrasse 21
Baar, 6340
Switzerland
Website novocure.com

Stock Details

Ticker Symbol NVCR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001645113
CUSIP Number G6674U108
ISIN Number JE00BYSS4X48
SIC Code 3841

Key Executives

Name Position
Frank Leonard Chief Executive Officer
William F. Doyle Executive Chairman
Barak Ben-Arye General Counsel
Christoph Brackmann Chief Financial Officer
Mukund Paravasthu Chief Operating Officer
Michael Puri Chief Human Resources Officer

Latest SEC Filings

Date Type Title
Mar 5, 2026 144 Filing
Mar 4, 2026 144 Filing
Mar 4, 2026 144 Filing
Mar 4, 2026 144 Filing
Mar 4, 2026 144 Filing
Mar 3, 2026 144 Filing
Mar 2, 2026 144 Filing
Mar 2, 2026 144 Filing
Feb 27, 2026 144 Filing
Feb 27, 2026 144 Filing